Malak Y Kotb from Cape Canaveral, FL, age 71

Professor

view source

Location:

Cincinnati, OH

Industry:

Higher Education

Work:

UC Ohio since 2008
Prof.& Director Midwest Center Infectious Disease @ UC COM & Senior Res. Career Scientist @ VAMC
UTMEM Jun 1985 - Nov 2008
Prof

Education:

University of Tennessee-Health Science Center 1977 - 1982
Ph.D., Biochemistry & Immunology UT & St Jude

Skills:

Biochemistry
Molecular Biology
Genetics
Microbiology
Cell Biology
Infectious Diseases
Systems Biology
Life Sciences
Pcr
Molecular Genetics
Research
Cell Culture
Immunology
Lifesciences
Animal Models
Epidemiology
Western Blotting
Qpcr
Cell
Flow Cytometry
Systems Genetics and Systems Biology Genetic Bases of Hu Diseases

Languages:

English

Former Chair And Current Proferssor

view source

Location:

Grand Forks, ND

Work:

Former Chair and Current Proferssor

Professor

view source

Location:

7520 Ridgewood Ave, Cape Canaveral, FL 32920

Industry:

Research

Work:

Vamc & Uc Cincinnati Oh
Professor

Professor

view source

Location:

Grand Forks, ND

Industry:

Higher Education

Work:

University of North Dakota School of Medicine and Health Sciences
Professor

Education:

University of Tennessee - Health Science Center College of Medicine 1977 - 1981
Doctorates, Doctor of Philosophy, Biochemistry, Philosophy, Immunology

Malak Kotb

view source

Location:

Grand Forks, ND

Industry:

Research

Work:

Und Amhs Academia Univ North Dakota
Professor and Chair Und Smhs

Malak Kotb

view source

Us Patents

Purified And Isolated Mat Ii Beta Subunit Nucleic Acids And Polypeptides And Therapeutic And Screening Methods Using Same
view source
US Patent:

20040259198, Dec 23, 2004
Filed:

Feb 20, 2004
Appl. No.:

10/783577
Inventors:

Malak Kotb - Memphis TN, US
H. Leighton LeGros - Memphis TN, US
Arthur Geller - Memphis TN, US
International Classification:

G01N033/53
C07H021/04
A61K039/395
C12N009/10
C07K016/40
US Classification:

435/069100, 435/320100, 435/325000, 435/193000, 530/388260, 435/338000, 424/146100, 536/023200
Abstract:

MAT II subunit proteins and cDNAs encoding the same. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed, along with methods of producing each. Isolated and purified antibodies to MAT II subunit homologs, and methods of producing the same, are also disclosed. MAT II subunit gene products are characterized as having activity in modulating the biological activity of MAT II. Thus, therapeutic methods involving these activities are also disclosed.

Purified And Isolated Mat Ii Subunit Nucleic Acids And Polypeptides And Therapeutic And Screening Methods Using Same
view source
US Patent:

6696279, Feb 24, 2004
Filed:

Jun 30, 2000
Appl. No.:

09/609133
Inventors:

Malak Kotb - Memphis TN
Arthur M. Geller - Memphis TN
Assignee:

University of Tennessee Research Foundation - Memphis TN
International Classification:

C12N 910
US Classification:

435193, 435 6, 4352523, 4353201, 435325, 435410, 536 232
Abstract:

MAT II subunit proteins and cDNAs encoding the same. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed, along with methods of producing each. Isolated and purified antibodies to MAT II subunit homologs, and methods of producing the same, are also disclosed. MAT II subunit gene products are characterized as having activity in modulating the biological activity of MAT II. Thus, therapeutic methods involving these activities are also disclosed.

Mat Ii Beta Subunit Rnai And Therapeutic Methods Using Same
view source
US Patent:

20110129461, Jun 2, 2011
Filed:

Apr 7, 2009
Appl. No.:

12/936780
Inventors:

Malak Kotb - Ft. Thomas KY, US
Arthur M. Geller - Ft. Thomas KY, US
Assignee:

UNIVERSITY OF CINCINNATI - Cincinnati OH
International Classification:

A61K 39/395
A61K 31/7105
A61K 38/00
C12N 5/071
C07H 21/02
C12N 15/63
C12P 19/34
C12N 5/10
A61P 35/00
A61P 35/02
US Classification:

4241331, 514 44 A, 4241301, 514 193, 435325, 536 245, 4353201, 435 911, 514 196
Abstract:

The presently disclosed subject matter generally relates to methods and compositions for modulating MAT II activity. More particularly, the presently disclosed subject matter relates to methods and compositions for inhibiting the expression of MAT II β subunit in a subject via RNAi by administering siRNA or shRNA molecules directed to MAT II β subunit. In some embodiments, the methods and compositions of the presently disclosed subject matter generally relates to the treatment of cancer. More particularly, the methods and compositions of the presently disclosed subject matter relates to the inhibition of MAT II β subunit for the treatment of leukemia.